As the managing attorney of The Cochran Firm, D.C., I am proud of the level of high-quality, experienced legal representation we offer for our Invokana injury clients. We are dedicated to providing our Invokana clients with effective and dedicated service and we are focused on the goal of achieving the highest possible level of compensation for injured victims and their families.
Our Invokana lawyers are consulting with individuals who have been injured by the side effects linked with Invokana, including myocardial infarction (heart attacks), kidney damage, pancreatitis, and ketoacidosis. This website is dedicated to providing you current medical and legal information regarding the Invokana litigation, including any potential monetary settlements or FDA recalls. In addition to Invokana, The Cochran Firm, D.C. is also monitoring legal and medical issues associated with other sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Farxiga, Xigduo, Jardiance, and Glyxambi.
We know there are lots of attorneys out there and it can be hard to tell them apart, but we believe there aren't nearly as many who have achieved our record of achievements on behalf of our client. Thank you for taking the time to look around our website and please get in touch if you have any questions.
- Free Consultation
- No Fees Until You Win
- Resources of a National Law Firm
- An attorney is assigned to your case
- Caring, Dedicated, Experienced Lawyers
- Proven Results
Invokana Kidney Injuries
What did the FDA say about Invokana?
With decades of collective legal experience, the team of seasoned attorneys at The Cochran Firm, D.C. represents victims of the type 2 diabetes drug Invokana, catastrophic personal injury, medical malpractice, defective products, and class action members in the Baltimore, Maryland, Virginia, Washington, D.C. and nationwide. Attorneys with The Cochran Firm, D.C. have been selected as 2013, 2014, and 2015 Super Lawyers, Best Lawyers in America, and have received top ratings from their peers, local and national publications and organizations, and clients for achieving successful verdicts and settlements for injury victims.
Free Case Evaluation
Fill out the form below to receive a free consultation on your case.
NO FEES UNTIL YOU WIN.
YOU PAY ABSOLUTELY NOTHING UNLESS
WE WIN YOUR CASE.
Honors and Awards
SGLT2 Inhibitors Investigated for Risks of Kidney Damage, Heart Attack, and Ketoacidosis
The FDA warned that Invokana® may cause serious side effects and health problems including ketoacidosis which may lead to kidney failure, heart attacks, hospitalization, coma or even death. The makers of Invokana® (Invokamet®) allegedly failed to warn patients and doctors of the increased risk of ketoacidosis. Type II diabetes patients who took Invokana® may be eligible for significant compensation. Invokana’s active ingredient is Canagliflozin.
Invokamet combines Invokana (canagliflozin) and metformin. Invokamet is made by Janssen Pharmaceuticals and is approved by the FDA for the treatment of type-2 diabetes. Invokamet may be linked to an increased risk of heart attack, stroke, ketoacidosis, and other side effects.
Pharmaceutical corporation AstraZeneca introduced Farxiga (dapagliflozin) in 2014 for type 2 diabetes treatment. Farxiga is a member of the same class of drugs as Invokana, which has been linked to serious side effects and potentially life-threatening health risks.
The Cochran Firm, D.C. is accepting Xigduo XR-induced injury claims. If you or somebody you know was diagnosed with diabetic ketoacidosis, suffered a heart attack, or other health problem, contact The Cochran Firm, D.C. at 202-682-5800 for a free, prompt, and confidential consultation.
Jardiance has been linked to a potentially increased risk of diabetic ketoacidosis (excessive acid build-up in the blood), a life-threatening complication that often requires hospitalization. Jardiance is part of the same class of drugs as Invokana. The Cochran Firm, D.C. is actively investigating Jardiance injury claims.
Glyxambi is a type-2 diabetes drug marketed by Boehringer Ingelheim. Glyxambi is a combination of empagliflozin (Jardiance) and linagliptin (Tradjenta). The prescription medication helps control blood-sugar levels. Empagliflozin is part of the class of diabetes medications that have recently been associated by the FDA with diabetic ketoacidosis.